Dazucorilant shows significant survival benefit in Phase 2 ALS trial
WHY IT MATTERS
If dazucorilant advances to Phase 3 testing, ALS patients may have access to a new treatment option that could extend survival, which is critical since current ALS therapies have limited effectiveness.
A new experimental drug called dazucorilant helped people with ALS live longer when given at a higher dose, according to a Phase 2 clinical trial. While the trial didn't fully meet all its main goals, the survival benefit was significant enough to be noteworthy. This suggests the drug may have promise for treating ALS, a disease that affects nerve cells controlling muscles.
People with amyotrophic lateral sclerosis (ALS) who received a high dose of the experimental therapy dazucorilant had a significantly higher chance of survival than patients given a lower dose or no treatment. That’s according to new analyses of data from the DAZALS Phase 2 clinical trial (NCT05407324), which failed to meet its main goals of […] The post Dazucorilant shows significant survival benefit in Phase 2 ALS trial appeared first on ALS News Today .